Window of Opportunity Study Targeting the Inflammatory Milieu

Exclusion Criteria

• •Known autoimmune condition, chronic steroid use, underlying immune disease (other than breast cancer), use of immunomodulatory prescription drugs for any medical condition
• •Known allergy or intolerance to fish oil, fish, non-steroidal anti-inflammatory drugs (NSAIDS), acetylsalicylic acid (ASA) or cyclooxygenase-2 (COX 2) inhibitors
• •Known bleeding diathesis or history of peptic ulcer disease; gastroesophageal reflux allowed if controlled
• •Currently taking greater than one 1000mg fish oil capsule daily or celecoxib at baseline, unless willing to stop consumption 1 week prior to starting study
• •History of stroke, transient ischemic attack (TIA) or coronary artery disease
• •The presence of other comorbid conditions known to impact immune function, (such as: type I diabetes, uncontrolled adult onset diabetes, severe chronic obstructive pulmonary disease (COPD), uncontrolled infection or known human immunodeficiency virus \[HIV\] infection)
• •Underlying psychiatric condition which would, in the opinion of the investigator, preclude compliance with study requirements
• •Women who are pregnant at time of breast cancer diagnosis and intend to continue the pregnancy; if pregnancy is terminated per patient's cancer decision making, they would be eligible for participation afterwards
• •History of other malignancy besides current diagnosis of breast cancer, unless definitively treated more than 5 years ago
• •Any history of Hodgkin's disease requiring mantle field irradiation
• •Any previous diagnosis of breast cancer